Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
2023年1月26日 - 6:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of January 2023
(Report No. 4)
Commission file number: 001-38041
SCISPARC LTD.
(Translation of registrant’s name into English)
20 Raul Wallenberg Street, Tower A,
Tel Aviv 6971916 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
CONTENTS
On January 25, 2023, SciSparc
Ltd. (the “Company”) issued a press release titled “SciSparc Announces Corporate
Restructuring Plan.” A copy of this press release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.
The press release attached
hereto as Exhibit 99.1 is incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-266047,
File No. 333-233417 and File No. 333-248670) and on Form S-8 (File No. 333-225773) filed with the Securities and
Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or
reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Date: January 25, 2023 |
By: |
/s/ Oz Adler |
|
Name: |
Oz Adler |
|
Title: |
Chief Executive Officer and
Chief Financial Officer |
Therapix Biosciences (NASDAQ:TRPX)
過去 株価チャート
から 10 2024 まで 11 2024
Therapix Biosciences (NASDAQ:TRPX)
過去 株価チャート
から 11 2023 まで 11 2024
Real-Time news about Therapix Biosciences Ltd (ナスダック市場): 0 recent articles
その他のScisparc Ltd.ニュース記事